News from the Bench
Discover what’s going on at CST, receive our latest application notes and tips, read our science features, and learn about our products.
CST Antibody Performance Guarantee
Find answers on our FAQs page.
- Additional protein information
- Analytical tools
PhosphoPlus® p38 MAPK (Thr180/Tyr182) Antibody Kit #9210
This product is discontinued
Gallery: PhosphoPlus® p38 MAPK (Thr180/Tyr182) Antibody Kit #9210
The PhosphoPlus® p38 MAPK (Thr180/Tyr182) Antibody Kit provides reagents and protocols for the rapid analysis of the phosphorylation status of p38 MAPK at Thr180/Tyr182.
Phospho-p38 MAPK Antibody detects phosphorylated threonine 180 and tyrosine 182 of p38 MAPK but does not appreciably cross-react with the corresponding phosphorylated forms of either p42/44 MAPK or SAPK/JNK. p38 MAPK (D13E1) XP® Rabbit mAb recognizes endogenous levels of total p38α, ß, or γ MAPK protein and does not recognize p38δ, SAPK/JNK, or p44/42 MAPK proteins.
Monoclonal activation state antibody is produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Thr180/Tyr182 of human p38 MAPK. Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human p38 protein.
p38 MAP kinase (MAPK), also called RK (1) or CSBP (2), is the mammalian orthologue of the yeast HOG kinase that participates in a signaling cascade controlling cellular responses to cytokines and stress (1-4). Four isoforms of p38 MAPK, p38α, β, γ (also known as Erk6 or SAPK3), and δ (also known as SAPK4) have been identified. Similar to the SAPK/JNK pathway, p38 MAPK is activated by a variety of cellular stresses including osmotic shock, inflammatory cytokines, lipopolysaccharide (LPS), UV light, and growth factors (1-5). MKK3, MKK6, and SEK activate p38 MAPK by phosphorylation at Thr180 and Tyr182. Activated p38 MAPK has been shown to phosphorylate and activate MAPKAP kinase 2 (3) and to phosphorylate the transcription factors ATF-2 (5), Max (6), and MEF2 (5-8).
SB203580 (4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-imidazole) is a selective inhibitor of p38 MAPK. This compound inhibits the activation of MAPKAPK-2 by p38 MAPK and subsequent phosphorylation of HSP27 (9). SB203580 inhibits p38 MAPK catalytic activity by binding to the ATP-binding pocket, but does not inhibit phosphorylation of p38 MAPK by upstream kinases (10).
For Research Use Only. Not For Use In Diagnostic Procedures. Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc. PhosphoPlus is a trademark of Cell Signaling Technology, Inc. LumiGLO is a registered trademark of Kirkegaard & Perry Laboratories.